EC approves Regeneron’s immunotherapy for cervical cancer
Pharmaceutical Technology
NOVEMBER 23, 2022
Libtayo is also indicated for treating progression of the disease on or following platinum-based chemotherapy. The trial enrolled 608 subjects in 14 countries, regardless of their PD-L1 expression status or histology and assessed Libtayo versus a chemotherapy of investigator's choice.
Let's personalize your content